CN103081893B - 一种心肌细胞的中药保存液及其应用 - Google Patents
一种心肌细胞的中药保存液及其应用 Download PDFInfo
- Publication number
- CN103081893B CN103081893B CN201110345947.2A CN201110345947A CN103081893B CN 103081893 B CN103081893 B CN 103081893B CN 201110345947 A CN201110345947 A CN 201110345947A CN 103081893 B CN103081893 B CN 103081893B
- Authority
- CN
- China
- Prior art keywords
- cardiac muscle
- muscle cell
- cell
- liquid
- preserves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002107 myocardial effect Effects 0.000 title abstract description 15
- 239000003761 preservation solution Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 57
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000000654 additive Substances 0.000 claims abstract description 23
- 230000000996 additive effect Effects 0.000 claims abstract description 23
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 117
- 239000007788 liquid Substances 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 6
- 239000002504 physiological saline solution Substances 0.000 abstract description 5
- 230000003833 cell viability Effects 0.000 abstract 1
- 210000002064 heart cell Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000006160 differential media Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 241000533367 Cnidium officinale Species 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
| 计数细胞数目 | 着色细胞数目 | 细胞存活率% | |
| 心肌细胞保存液I | 500 | 69±3 | 87.0±1 |
| 心肌细胞保存液II | 500 | 12±2 | 97±0.7 |
| 心肌细胞保存液III | 500 | 9±1 | 98.0±0.3 |
| 计数细胞数目 | 着色细胞数目 | 细胞存活率% | |
| 心肌细胞保存液I | 300 | 34±4 | 89.2±0.3 |
| 心肌细胞保存液II | 300 | 7±1 | 97.7±0.3 |
| 心肌细胞保存液III | 300 | 8±1 | 97.7±0.3 |
| 计数细胞数目 | 着色细胞数目 | 细胞存活率% | |
| 心肌细胞保存液I | 300 | 40±5 | 86.7±0.3 |
| 心肌细胞保存液II | 300 | 5±1 | 98.3±0.3 |
| 心肌细胞保存液III | 300 | 7±2 | 97.7±0.3 |
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110345947.2A CN103081893B (zh) | 2011-11-07 | 2011-11-07 | 一种心肌细胞的中药保存液及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110345947.2A CN103081893B (zh) | 2011-11-07 | 2011-11-07 | 一种心肌细胞的中药保存液及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103081893A CN103081893A (zh) | 2013-05-08 |
| CN103081893B true CN103081893B (zh) | 2014-09-03 |
Family
ID=48195437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110345947.2A Active CN103081893B (zh) | 2011-11-07 | 2011-11-07 | 一种心肌细胞的中药保存液及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103081893B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115698263B (zh) * | 2020-04-09 | 2025-06-13 | 深圳百洋智心医学研究有限公司 | 用于心肌细胞冻存的组合物 |
| CN114762496B (zh) * | 2021-01-11 | 2023-11-07 | 南京艾尔普再生医学科技有限公司 | 心肌细胞冻存液及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1633848A (zh) * | 2004-12-07 | 2005-07-06 | 中国人民解放军第二军医大学 | 一种肾脏保存液 |
| CN101496512A (zh) * | 2008-02-01 | 2009-08-05 | 扬子江药业集团上海海尼药业有限公司 | 一种器官保存液及其制备方法 |
| CN102228016A (zh) * | 2011-04-18 | 2011-11-02 | 上海安集协康生物技术有限公司 | 一种神经干细胞冻存复苏的方法 |
| EP2412800A1 (en) * | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
-
2011
- 2011-11-07 CN CN201110345947.2A patent/CN103081893B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1633848A (zh) * | 2004-12-07 | 2005-07-06 | 中国人民解放军第二军医大学 | 一种肾脏保存液 |
| CN101496512A (zh) * | 2008-02-01 | 2009-08-05 | 扬子江药业集团上海海尼药业有限公司 | 一种器官保存液及其制备方法 |
| EP2412800A1 (en) * | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| CN102228016A (zh) * | 2011-04-18 | 2011-11-02 | 上海安集协康生物技术有限公司 | 一种神经干细胞冻存复苏的方法 |
Non-Patent Citations (4)
| Title |
|---|
| 严全能 等.心肌干细胞的体外扩增方法研究.《南方医科大学学报》.2009,第29卷(第5期),第1069-1070页. |
| 川芎嗪预处理对心肌缺血再灌注损伤保护作用机制的研究;梁日欣 等;《中药药理与临床》;20010630;第17卷(第3期);第8-9页 * |
| 心肌干细胞的体外扩增方法研究;严全能 等;《南方医科大学学报》;20090531;第29卷(第5期);第1069-1070页 * |
| 梁日欣 等.川芎嗪预处理对心肌缺血再灌注损伤保护作用机制的研究.《中药药理与临床》.2001,第17卷(第3期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103081893A (zh) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12156891B2 (en) | Cardiac stem cells for cardiac repair | |
| CN104082277B (zh) | 一种人外周血单个核细胞的冻存保护剂及保存方法 | |
| JP6548714B2 (ja) | 放射線照射または化学物質による傷害を治療するための方法 | |
| Chen et al. | Application of adipose-derived stem cells in heart disease | |
| Drela et al. | Endothelial progenitor cells in diabetic foot syndrome | |
| CN103667187B (zh) | 一种人脂肪干细胞的分离培养方法和干细胞库的构建方法 | |
| CN104711221B (zh) | 从成人外周血中自动化分离免疫细胞并提取prp的方法 | |
| CN106982821A (zh) | 脐带间充质干细胞临床冻存保护液组合物及其用途 | |
| CN108633877A (zh) | 一种人脐带间充质干细胞外泌体冻干粉及其制备的方法 | |
| CN108056095A (zh) | 一种脂肪间充质干细胞运输保护液及其应用 | |
| CN106212443B (zh) | 临床级细胞保护液及其制备方法和应用 | |
| US20150231244A1 (en) | Regenerative cell and adipose-derived stem cell processing system and method | |
| CN109674819B (zh) | 胎盘间充质干细胞制剂及其治疗硬化病的用途 | |
| Turner et al. | Clinical-based cell therapies for heart disease—current and future state | |
| CN110193025B (zh) | 人脂肪干细胞来源的外泌体冻干粉及其制备方法和应用 | |
| CN106798724A (zh) | 一种骨髓间充质干细胞注射液及其制备方法和应用 | |
| Liu et al. | Stem cell and idiopathic pulmonary fibrosis: mechanisms and treatment | |
| EJ Reinders et al. | Mesenchymal stromal cell therapy for cardio renal disorders | |
| CN109964922A (zh) | 一种骨髓间充质干细胞冻存液及冻存方法 | |
| CN103081893B (zh) | 一种心肌细胞的中药保存液及其应用 | |
| Chen et al. | Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy? | |
| CN105454220A (zh) | 一种胎盘保存方法、胎盘保存液及其制备方法 | |
| CN110193026B (zh) | 干细胞有效成分提取物的制备及其与干细胞外泌体的组合和应用 | |
| US20210171579A1 (en) | Inhibitor using plant cyclopeptide as effective component for lipid metabolic abnormalities in cancer cells and uses thereof | |
| CN116867370A (zh) | 冻干间充质干细胞 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing QMLC Stem Cell Technology Co., Ltd. Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100084, C building, Tsinghua Science and technology building, No. 1 Zhongguancun East Road, Beijing, Haidian District, 301 Applicant after: Beijing QMLC Stem Cell Technology Co., Ltd. Address before: 100097 Beijing city Haidian District minzhuang Road No. 3, Tsinghua Science Park building 204 Yuquan Huigu 7 Applicant before: Beijing QMLC Stem Cell Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |